We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...
GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...
Key drugs Blenrep and Depemokimab show significant potential, with impressive Phase 3 results, expected to boost GSK's revenues by an extra £7 billion. Despite some IRA and clinical trial risks ...
In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks. The stock market extended its winning streak on Wednesday, closing firmer as investors ...
19d
Zacks.com on MSNGSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term OutlookGSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks Consensus Estimate of 53 cents. Core earnings declined 20% year over year ...
This year, GSK expects to launch five new products/line extensions, including Blenrep (relaunch in multiple myeloma), depemokimab (for severe asthma and chronic rhinosinusitis with nasal polyps ...
including Blenrep for multiple myeloma and depemokimab for severe asthma. CEO Emma Walmsley emphasized prioritizing R&D in respiratory, oncology, and HIV treatments. For 2025, GSK expects turnover ...
plus over 4 billion pound sterling in combined peak sales from Nucala and the near-market long-acting IL-5 drug depemokimab, will help boost the contribution of GSK's specialty medicines portfolio ...
Strong full-year trading and an improving outlook have propelled GSK’s share price higher, as Royston Wild explains. The content of this article is provided for information purposes only and is ...
GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential functional cure for the infectious disease. On a media call Wednesday morning ...
GSK (GSK.L) shares ended 2024 on a sour note after what proved to be a rollercoaster year. The pharma giant dropped 7% over the 12 months, as worries over Zantac litigation and potential shake-ups in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results